| Title |
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer
|
|---|---|
| Published in |
Journal of Cancer Research and Clinical Oncology, November 2017
|
| DOI | 10.1007/s00432-017-2539-7 |
| Pubmed ID | |
| Authors |
Holm Eggemann, Udo Altmann, Serban-Dan Costa, Atanas Ignatov |
| Abstract |
Our goal was to compare the survival advantage of tamoxifen (TAM) and aromatase inhibitor (AI) in female (FBC) and male breast cancer (MBC). We performed a retrospective study of 2785 FBC and 257 MBC patients treated with hormonal therapy. The median follow-up was 106 months (range 3-151 months) and 42 months (range 2-115 months) for FBC and MBC, respectively. The patients were divided into two groups according to the hormonal therapy used: TAM-treated and AI-treated. MBC was characterized by older age, advanced tumor stage, and higher rate of lymph node metastases, in comparison with FBC. Matching analysis was performed using six prognostic criteria: patient age, tumor stage, tumor grade, lymph node status, human epidermal growth factor receptor (HER2) status, and administration of chemotherapy. The female and male patients were matched 2:1. In this analysis, 316 women and 158 men treated with TAM, and 60 women and 30 men treated with AI, were included. The overall survival (OS) was estimated by the Kaplan-Meier method and was compared between FBC and MBC. TAM-treated FBC and MBC patients had similar 5-year OS, 85.1 and 89.2%, respectively (p = 0.972). Notably, FBC patients treated with AI had significantly greater 5-year OS (85.0%) in comparison with AI-treated MBC patients (5-year OS of 73.3%; p = 0.028). The OS of TAM-treated patients with MBC was similar to the OS of TAM-treated FBC patients, whereas AI treatment is associated with poorer survival of MBC patients. |
X Demographics
The data shown below were collected from the profiles of 10 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 10% |
| Canada | 1 | 10% |
| Unknown | 8 | 80% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 80% |
| Practitioners (doctors, other healthcare professionals) | 1 | 10% |
| Scientists | 1 | 10% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 52 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 13% |
| Student > Doctoral Student | 6 | 12% |
| Student > Master | 4 | 8% |
| Lecturer | 2 | 4% |
| Librarian | 2 | 4% |
| Other | 8 | 15% |
| Unknown | 23 | 44% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 10% |
| Nursing and Health Professions | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 3 | 6% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 5 | 10% |
| Unknown | 23 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2019.
All research outputs
#2,116,640
of 23,815,455 outputs
Outputs from Journal of Cancer Research and Clinical Oncology
#57
of 2,632 outputs
Outputs of similar age
#43,241
of 331,071 outputs
Outputs of similar age from Journal of Cancer Research and Clinical Oncology
#3
of 24 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,632 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,071 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.